Drug Profile
Research programme: vasopressin receptor antagonists - Johnson and Johnson
Alternative Names: RWJ-339489Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Benzodiazepines
- Mechanism of Action Vasopressin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Genitourinary disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Genitourinary-disorders in USA
- 09 Sep 2004 Data presented at the 228th American Chemical Society National Meeting (228th-ACS-2004) have been added to the adverse events and pharmacokinetics sections